Tschen Shuen-Ing, Dhawan Sangeeta, Gurlo Tatyana, Bhushan Anil
Larry L. Hillblom Islet Research Center, Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Diabetes. 2009 Jun;58(6):1312-20. doi: 10.2337/db08-1651. Epub 2009 Feb 19.
The aim of this study was to elucidate whether age plays a role in the expansion or regeneration of beta-cell mass.
We analyzed the capacity of beta-cell expansion in 1.5- and 8-month-old mice in response to a high-fat diet, after short-term treatment with the glucagon-like peptide 1 (GLP-1) analog exendin-4, or after streptozotocin (STZ) administration.
Young mice responded to high-fat diet by increasing beta-cell mass and beta-cell proliferation and maintaining normoglycemia. Old mice, by contrast, did not display any increases in beta-cell mass or beta-cell proliferation in response to high-fat diet and became diabetic. To further assess the plasticity of beta-cell mass with respect to age, young and old mice were injected with a single dose of STZ, and beta-cell proliferation was analyzed to assess the regeneration of beta-cells. We observed a fourfold increase in beta-cell proliferation in young mice after STZ administration, whereas no changes in beta-cell proliferation were observed in older mice. The capacity to expand beta-cell mass in response to short-term treatment with the GLP-1 analog exendin-4 also declined with age. The ability of beta-cell mass to expand was correlated with higher levels of Bmi1, a polycomb group protein that is known to regulate the Ink4a locus, and decreased levels of p16(Ink4a)expression in the beta-cells. Young Bmi1(-/-) mice that prematurely upregulate p16(Ink4a)failed to expand beta-cell mass in response to exendin-4, indicating that p16(Ink4a)levels are a critical determinant of beta-cell mass expansion.
beta-Cell proliferation and the capacity of beta-cells to regenerate declines with age and is regulated by the Bmi1/p16(Ink4a)pathway.
本研究旨在阐明年龄是否在β细胞量的扩增或再生中起作用。
我们分析了1.5月龄和8月龄小鼠在高脂饮食、用胰高血糖素样肽1(GLP-1)类似物艾塞那肽-4短期治疗或注射链脲佐菌素(STZ)后β细胞扩增的能力。
年轻小鼠通过增加β细胞量和β细胞增殖来应对高脂饮食,并维持血糖正常。相比之下,老年小鼠在高脂饮食刺激下未出现β细胞量或β细胞增殖增加,且患上了糖尿病。为进一步评估β细胞量随年龄的可塑性,给年轻和老年小鼠注射单剂量STZ,并分析β细胞增殖以评估β细胞的再生情况。我们观察到,注射STZ后年轻小鼠的β细胞增殖增加了四倍,而老年小鼠的β细胞增殖未发生变化。β细胞量对GLP-1类似物艾塞那肽-4短期治疗的扩增能力也随年龄下降。β细胞量的扩增能力与较高水平的Bmi1相关,Bmi1是一种已知可调节Ink4a基因座的多梳蛋白家族蛋白,且β细胞中p16(Ink4a)表达水平降低。过早上调p16(Ink4a)的年轻Bmi1(-/-)小鼠在接受艾塞那肽-4治疗后未能扩增β细胞量,这表明p16(Ink4a)水平是β细胞量扩增的关键决定因素。
β细胞增殖及β细胞再生能力随年龄下降,并受Bmi1/p16(Ink4a)通路调控。